{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:16:42Z","timestamp":1785421002723,"version":"3.56.0"},"reference-count":168,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kazan Federal University Strategic Academic Leadership Program","award":["PRIORITY-2030"],"award-info":[{"award-number":["PRIORITY-2030"]}]},{"award":["PRIORITY-2030"],"award-info":[{"award-number":["PRIORITY-2030"]}],"id":[{"id":"https:\/\/ror.org\/05256ym39","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Peripheral arterial disease and critical limb-threatening ischemia remain major clinical challenges, particularly in patients who are not candidates for surgical or endovascular revascularization. These limitations have stimulated extensive investigation into therapeutic angiogenesis using gene therapy approaches. This review summarizes experimental and clinical studies employing non-viral and viral gene delivery systems for the transfer of angiogenic factors, including VEGF, FGF-2, HGF, HIF-1\u03b1, and SDF-1. Particular attention is given to vector platforms, study design, patient populations, clinical endpoints, and safety outcomes reported in preclinical investigations and clinical trials. Although several studies demonstrated biological activity and favorable safety profiles, randomized trials such as RAVE and TAMARIS failed to demonstrate consistent and significant clinical efficacy. These findings emphasize the translational challenges associated with therapeutic angiogenesis and highlight the persistent gap between promising preclinical data and clinical outcomes in humans. Future progress in the field will likely depend on improved vector engineering, tissue-specific and regulated gene expression systems, optimized delivery strategies, and the integration of gene therapy with emerging regenerative technologies.<\/jats:p>","DOI":"10.3390\/cells15121104","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:59:38Z","timestamp":1781773178000},"page":"1104","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Angiogenic Gene Therapy for Lower Extremity Ischemia: Experimental Advances and Clinical Experience"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6836-7285","authenticated-orcid":false,"given":"Igor","family":"Samatoshenkov","sequence":"first","affiliation":[{"name":"Department of Vascular and Endovascular Surgery, Klinik Mittelbaden Rastatt-Forbach, 76437 Rastatt, Germany"},{"name":"Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zakirova","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Samatoshenkova","sequence":"additional","affiliation":[{"name":"SAHI Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, 420138 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9427-5739","authenticated-orcid":false,"given":"Albert","family":"Rizvanov","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia"},{"name":"Division of Medical and Biological Sciences, Tatarstan Academy of Sciences, 420111 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9435-340X","authenticated-orcid":false,"given":"Yana","family":"Mukhamedshina","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia"},{"name":"Division of Medical and Biological Sciences, Tatarstan Academy of Sciences, 420111 Kazan, Russia"},{"name":"Department of Histology, Cytology and Embryology, Kazan State Medical University, 420012 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Trenner, M., Knappich, C., Bohmann, B., Heuberger, S., Eckstein, H.H., and Kuehnl, A. (2022). Utilization and Regional Differences of In-Patient Services for Peripheral Arterial Disease and Acute Limb Ischemia in Germany: Secondary Analysis of Nationwide DRG Data. J. Clin. Med., 11.","DOI":"10.3390\/jcm11082116"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1001\/jama.2021.2126","article-title":"Lower Extremity Peripheral Artery Disease Without Chronic Limb-Threatening Ischemia: A Review","volume":"325","author":"Polonsky","year":"2021","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"ref_4","first-page":"362","article-title":"Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment","volume":"99","author":"Firnhaber","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tcm.2019.04.002","article-title":"Lower extremity critical limb ischemia: A review of clinical features and management","volume":"30","author":"Levin","year":"2020","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1161\/CIRCULATIONAHA.106.174526","article-title":"ACC\/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery\/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC\/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation","volume":"113","author":"Hirsch","year":"2006","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J. Vasc. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrcardio.2013.70","article-title":"Therapeutic angiogenesis for critical limb ischaemia","volume":"10","author":"Annex","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"69","author":"Conte","year":"2019","journal-title":"J. Vasc. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Makarevich, P.I., Dergilev, K.V., Tsokolaeva, Z.I., Boldyreva, M.A., Shevchenko, E.K., Gluhanyuk, E.V., Gallinger, J.O., Menshikov, M.Y., and Parfyonova, Y.V. (2018). Angiogenic and pleiotropic effects of VEGF165 and HGF combined gene therapy in a rat model of myocardial infarction. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197566"},{"key":"ref_12","first-page":"183","article-title":"A Review and Proposed Classification System for the No-Option Patient with Chronic Limb-Threatening Ischemia","volume":"28","author":"Kim","year":"2021","journal-title":"J. Endovasc. Ther. Off. J. Int. Soc. Endovasc. Spec."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cmet.2012.11.012","article-title":"Vascular complications of diabetes: Mechanisms of injury and protective factors","volume":"17","author":"King","year":"2013","journal-title":"Cell Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: From pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1161\/CIRCRESAHA.115.306884","article-title":"Vascular Complications of Diabetes","volume":"118","author":"Beckman","year":"2016","journal-title":"Circ. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.blre.2009.07.002","article-title":"Basic mechanisms and pathogenesis of venous thrombosis","volume":"23","author":"Esmon","year":"2009","journal-title":"Blood Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","article-title":"Basic and therapeutic aspects of angiogenesis","volume":"146","author":"Potente","year":"2011","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1161\/01.CIR.0000128595.79378.FA","article-title":"Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: Angiogenic cytokines","volume":"109","author":"Losordo","year":"2004","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Everts, P.A., Lana, J.F., Onishi, K., Buford, D., Peng, J., Mahmood, A., Fonseca, L.F., van Zundert, A., and Podesta, L. (2023). Angiogenesis and Tissue Repair Depend on Platelet Dosing and Bioformulation Strategies Following Orthobiological Platelet-Rich Plasma Procedures: A Narrative Review. Biomedicines, 11.","DOI":"10.20944\/preprints202306.0745.v1"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Scopelliti, F., Cattani, C., Dimartino, V., Mirisola, C., and Cavani, A. (2022). Platelet Derivatives and the Immunomodulation of Wound Healing. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158370"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41536-021-00189-1","article-title":"VEGF-A, PDGF-BB and HB-EGF engineered for promiscuous super affinity to the extracellular matrix improve wound healing in a model of type 1 diabetes","volume":"6","author":"White","year":"2021","journal-title":"npj Regen. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13505","DOI":"10.1073\/pnas.0906670106","article-title":"The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues","volume":"106","author":"Thangarajah","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.110.217117","article-title":"Activation of protein kinase C isoforms and its impact on diabetic complications","volume":"106","author":"Geraldes","year":"2010","journal-title":"Circ. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/cts.12977","article-title":"Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor","volume":"14","author":"Kessler","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12265-020-10066-9","article-title":"Double VEGF\/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus","volume":"14","author":"Antkiewicz","year":"2021","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: Therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/j.1460-2075.1986.tb04530.x","article-title":"Human basic fibroblast growth factor: Nucleotide sequence and genomic organization","volume":"5","author":"Abraham","year":"1986","journal-title":"EMBO J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0014-4835(79)90038-1","article-title":"The angiogenic activity of the fibroblast and epidermal growth factor","volume":"28","author":"Gospodarowicz","year":"1979","journal-title":"Exp. Eye Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1073\/pnas.81.17.5364","article-title":"Isolation and partial molecular characterization of pituitary fibroblast growth factor","volume":"81","author":"Baird","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","first-page":"5629","article-title":"A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines","volume":"46","author":"Senger","year":"1986","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.bbrc.2012.08.021","article-title":"Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells","volume":"425","author":"Ferrara","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vascular permeability factor, an endothelial cell mitogen related to PDGF","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1002\/j.1460-2075.1989.tb08557.x","article-title":"Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells","volume":"8","author":"Schilling","year":"1989","journal-title":"EMBO J."},{"key":"ref_36","first-page":"519","article-title":"Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family","volume":"5","author":"Shibuya","year":"1990","journal-title":"Oncogene"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/0006-291X(92)90483-2","article-title":"Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor","volume":"187","author":"Terman","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1084\/jem.178.6.2077","article-title":"The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells","volume":"178","author":"Kaipainen","year":"1993","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9267","DOI":"10.1073\/pnas.88.20.9267","article-title":"Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor","volume":"88","author":"Maglione","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/j.1460-2075.1996.tb00521.x","article-title":"A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases","volume":"15","author":"Joukov","year":"1996","journal-title":"EMBO J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.277.5323.242","article-title":"Pericyte loss and microaneurysm formation in PDGF-B-deficient mice","volume":"277","author":"Lindahl","year":"1997","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1242\/dev.126.14.3047","article-title":"Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse","volume":"126","author":"Lindahl","year":"1999","journal-title":"Development"},{"key":"ref_43","first-page":"99","article-title":"tie2, a putative protein tyrosine kinase from a new class of cell surface receptor","volume":"9","author":"Runting","year":"1993","journal-title":"Growth Factors"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0092-8674(00)81812-7","article-title":"Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning","volume":"87","author":"Davis","year":"1996","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1172\/JCI117018","article-title":"Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model","volume":"93","author":"Takeshita","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1089\/hum.1996.7.8-959","article-title":"Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease","volume":"7","author":"Isner","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0741-5214(98)70022-9","article-title":"Treatment of thromboangiitis obliterans (Buerger\u2019s disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results","volume":"28","author":"Isner","year":"1998","journal-title":"J. Vasc. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1161\/01.CIR.97.12.1114","article-title":"Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia","volume":"97","author":"Baumgartner","year":"1998","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","article-title":"Vascular endothelial growth factor signaling in health and disease: From molecular mechanisms to therapeutic perspectives","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3892\/etm.2025.12893","article-title":"Advances in the molecular signaling mechanisms of VEGF\/VEGFR2 in fundus neovascularization disease (Review)","volume":"30","author":"Li","year":"2025","journal-title":"Exp. Ther. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1091\/mbc.4.12.1317","article-title":"The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF","volume":"4","author":"Park","year":"1993","journal-title":"Mol. Biol. Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/cvr\/cvq105","article-title":"Vascular endothelial growth factors and vascular permeability","volume":"87","author":"Bates","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/01.RES.0000118600.91698.BB","article-title":"Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability","volume":"94","author":"Cao","year":"2004","journal-title":"Circ. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/wound.2013.0517","article-title":"Vascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutaneous Wound Repair","volume":"3","author":"Johnson","year":"2014","journal-title":"Adv. Wound Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1161\/CIRCULATIONAHA.104.526954","article-title":"Vascular endothelial growth factor is required for coronary collateral growth in the rat","volume":"112","author":"Toyota","year":"2005","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling is required for vascular homeostasis","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1167\/iovs.66.12.45","article-title":"Endothelial-Pericyte Interactions Regulate Angiogenesis via VEGFR2 Signaling During Retinal Development and Disease","volume":"66","author":"Lin","year":"2025","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Thompson, M.B., Tirupattur, S.P., Vishwakarma, N., and Katwa, L.C. (2025). Essential Pieces of the Puzzle: The Roles of VEGF and Dopamine in Aging. Cells, 14.","DOI":"10.3390\/cells14151178"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"de Gea, P., Benkeder, S., Bouvet, P., Aimard, M., Chounlamountri, N., Honnorat, J., Do, L.D., and Meissirel, C. (2023). VEGF controls microglial phagocytic response to amyloid-\u03b2. Front. Cell Neurosci., 17.","DOI":"10.3389\/fncel.2023.1264402"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12929-025-01128-8","article-title":"Beyond vessels: Unraveling the impact of VEGFs on neuronal functions and structure","volume":"32","author":"Aksan","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"van der Mescht, M.A., Steel, H.C., Anderson, R., and Rossouw, T.M. (2024). Vascular endothelial growth factor A: Friend or foe in the pathogenesis of HIV and SARS-CoV-2 infections?. Front. Cell Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1458195"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Schawe, L., Raude, B., Carstens, J.C., Hinterseher, I., Hein, R.D., Omran, S., Berger, G., Hering, N.A., Buerger, M., and Greiner, A. (2022). Effect of Revascularization on Intramuscular Vascular Endothelial Growth Factor Levels in Peripheral Arterial Disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020471"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cytogfr.2005.01.004","article-title":"Fibroblast growth factor\/fibroblast growth factor receptor system in angiogenesis","volume":"16","author":"Presta","year":"2005","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MOH.0b013e3282f97d98","article-title":"Fibroblast growth factor regulation of neovascularization","volume":"15","author":"Murakami","year":"2008","journal-title":"Curr. Opin. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/10739680591003413","article-title":"Arteriolization of capillaries and FGF-2 upregulation in skeletal muscles of patients with chronic peripheral arterial disease","volume":"12","author":"Baum","year":"2005","journal-title":"Microcirculation"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Ye, W., Wang, Y.D., and Chen, W.D. (2022). HGF\/c-Met: A Key Promoter in Liver Regeneration. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.808855"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1161\/01.HYP.37.2.581","article-title":"Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells","volume":"37","author":"Nakagami","year":"2001","journal-title":"Hypertension"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.CIR.0000055331.41937.AA","article-title":"Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1","volume":"107","author":"Tomita","year":"2003","journal-title":"Circulation"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.ymthe.2019.11.001","article-title":"Gene Therapy of Critical Limb Ischemia Enters Clinical Use","volume":"27","year":"2019","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lin, Y.M., Huang, Y.L., Fong, Y.C., Tsai, C.H., Chou, M.C., and Tang, C.H. (2012). Hepatocyte growth factor increases vascular endothelial growth factor-A production in human synovial fibroblasts through c-Met receptor pathway. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050924"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Li, B., Khalil, A.M., Abuhalimeh, L., Shaikh, F., Younes, H., Abuhalimeh, B., Zamzam, A., Abdin, R., and Qadura, M. (2025). Association of Hepatocyte Growth Factor and Angiopoietin-2 with Systemic Cardiovascular Risk in Patients with Peripheral Artery Disease. J. Clin. Med., 14.","DOI":"10.3390\/jcm14124031"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"C174","DOI":"10.1152\/ajpcell.2000.278.1.C174","article-title":"Hepatocyte growth factor affects satellite cell activation and differentiation in regenerating skeletal muscle","volume":"278","author":"Miller","year":"2000","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1210\/jcem.84.7.5826","article-title":"Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease","volume":"84","author":"Yoshitomi","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/s12276-023-01096-9","article-title":"Vascular regeneration and skeletal muscle repair induced by long-term exposure to SDF-1\u03b1 derived from engineered mesenchymal stem cells after hindlimb ischemia","volume":"55","author":"Kim","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s10735-021-10008-y","article-title":"SDF-1 secreted by mesenchymal stem cells promotes the migration of endothelial progenitor cells via CXCR4\/PI3K\/AKT pathway","volume":"52","author":"Wang","year":"2021","journal-title":"J. Mol. Histol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3892\/etm.2020.9471","article-title":"Role of the stromal cell derived factor-1 in the biological functions of endothelial progenitor cells and its underlying mechanisms","volume":"21","author":"Cun","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jvs.2009.10.044","article-title":"Angiogenic effects of stromal cell-derived factor-1 (SDF-1\/CXCL12) variants in vitro and the in vivo expressions of CXCL12 variants and CXCR4 in human critical leg ischemia","volume":"51","author":"Ho","year":"2010","journal-title":"J. Vasc. Surg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"143209","DOI":"10.1155\/2012\/143209","article-title":"Stromal-Cell-Derived Factor-1 (SDF-1)\/CXCL12 as Potential Target of Therapeutic Angiogenesis in Critical Leg Ischaemia","volume":"2012","author":"Ho","year":"2012","journal-title":"Cardiol. Res. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Heo, J.-I., Kim, K.I., Woo, S.-K., Kim, J.S., Choi, K.J., Lee, H.-J., and Kim, K.S. (2019). Stromal Cell-Derived Factor 1 Protects Brain Vascular Endothelial Cells from Radiation-Induced Brain Damage. Cells, 8.","DOI":"10.3390\/cells8101230"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2012.08.018","article-title":"Angiopoietins in angiogenesis","volume":"328","author":"Fagiani","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI58832","article-title":"Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling","volume":"122","author":"Felcht","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Akwii, R.G., Sajib, M.S., Zahra, F.T., and Mikelis, C.M. (2019). Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology. Cells, 8.","DOI":"10.3390\/cells8050471"},{"key":"ref_84","first-page":"2390174","article-title":"Circulating Angiogenic Growth Factors in Diabetes Patients with Peripheral Arterial Disease and Exertional Leg Pain in Ghana","volume":"2017","author":"Yeboah","year":"2017","journal-title":"Int. J. Vasc. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1010450023203","article-title":"Angiogenin and its role in angiogenesis","volume":"35","author":"Shestenko","year":"2001","journal-title":"Mol. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1021\/bi9005094","article-title":"Ribonuclease inhibitor regulates neovascularization by human angiogenin","volume":"48","author":"Dickson","year":"2009","journal-title":"Biochemistry"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1745-7270.2008.00442.x","article-title":"Mechanisms of action of angiogenin","volume":"40","author":"Gao","year":"2008","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.onc.1208223","article-title":"Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis","volume":"24","author":"Kishimoto","year":"2005","journal-title":"Oncogene"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/B978-0-12-394306-4.00011-3","article-title":"New insights into the role of angiogenin in actin polymerization","volume":"295","author":"Pyatibratov","year":"2012","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/00033197211004393","article-title":"Angiogenin-A Proposed Biomarker for Cardiovascular Disease-Is Not Associated with Long-Term Survival in Patients with Peripheral Artery Disease","volume":"72","author":"Pesau","year":"2021","journal-title":"Angiology"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Bui, B.P., Nguyen, P.L., Lee, K., and Cho, J. (2022). Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain. Cancers, 14.","DOI":"10.3390\/cancers14246054"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"549412","DOI":"10.1155\/2015\/549412","article-title":"Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies","volume":"2015","author":"Zimna","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2045-824X-5-15","article-title":"Cardiac angiogenesis directed by stable Hypoxia Inducible Factor-1","volume":"5","author":"Walton","year":"2013","journal-title":"Vasc. Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5758\/vsi.210011","article-title":"Is Biochemical Follow Up Possible in Peripheral Arterial Disease Treatment: Hypoxia Inducible Factor-1 Alpha?","volume":"37","author":"Ketenciler","year":"2021","journal-title":"Vasc. Spec. Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/157016111795495602","article-title":"Hypoxia-inducible factor-1 in arterial disease: A putative therapeutic target","volume":"9","author":"Kasivisvanathan","year":"2011","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00125-021-05380-z","article-title":"Hypoxia and hypoxia-inducible factors in diabetes and its complications","volume":"64","author":"Catrina","year":"2021","journal-title":"Diabetologia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/1566523222666220921112753","article-title":"Gene Therapy Cargoes Based on Viral Vector Delivery","volume":"23","author":"Lundstrom","year":"2023","journal-title":"Curr. Gene Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejps.2010.03.019","article-title":"Gene delivery by lipoplexes and polyplexes","volume":"40","author":"Sun","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Li, X., Le, Y., Zhang, Z., Nian, X., Liu, B., and Yang, X. (2023). Viral Vector-Based Gene Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097736"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.2174\/156802612803531342","article-title":"Therapeutic option of plasmid-DNA based gene transfer","volume":"12","author":"Taniyama","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Samatoshenkov, I.V., Aimaletdinov, A.M., Zakirova, E.Y., Kalmykov, E.L., Khodzhibaev, R., Samatoshenkova, Y.M., Ganiev, I.M., Kadyrov, M.S., and Mukhamedshina, Y.O. (2025). Extended Toxicity, Genotoxicity, and Mutagenicity of Combination of pBudK-coVEGF-coANG and pBudK-coGDNF Plasmids in Preclinical Trials. Biomedicines, 13.","DOI":"10.3390\/biomedicines13051223"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6","DOI":"10.23868\/202003001","article-title":"Gene therapy in regenerative medicine: Latest achievements and actual directions of development","volume":"15","author":"Slobodkina","year":"2020","journal-title":"Genes. Cells"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/gt.2010.43","article-title":"Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation","volume":"17","author":"Ferraro","year":"2010","journal-title":"Gene Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.gt.3301379","article-title":"Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: Preclinical study for treatment of peripheral arterial disease","volume":"8","author":"Taniyama","year":"2001","journal-title":"Gene Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/hc4401.098470","article-title":"Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: Molecular mechanisms of delayed angiogenesis in diabetes","volume":"104","author":"Taniyama","year":"2001","journal-title":"Circulation"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/gt.2009.30","article-title":"Repeated, but not single, VEGF gene transfer affords protection against ischemic muscle lesions in rabbits with hindlimb ischemia","volume":"16","author":"Olea","year":"2009","journal-title":"Gene Ther."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Stafeev, I.I.S., Boldyreva, M.A., Michurina, S.S., Agareva, M.Y., Radnaeva, A.V., Menshikov, M.Y., Hu, Y.-C., Makarevich, P.I., and Parfyonova, Y.V. (2022). The Efficacy of HGF\/VEGF Gene Therapy for Limb Ischemia in Mice with Impaired Glucose Tolerance: Shift from Angiogenesis to Axonal Growth and Oxidative Potential in Skeletal Muscle. Cells, 11.","DOI":"10.3390\/cells11233824"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/hum.2024.245","article-title":"Advancements in Gene-Based Therapeutic Angiogenesis for Chronic Limb-Threatening Ischemia","volume":"36","author":"Wang","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Bar\u0107, P., Antkiewicz, M., Fr\u0105czkowska-Sioma, K., Kupczy\u0144ska, D., Lubieniecki, P., Witkiewicz, W., Ma\u0142odobra-Mazur, M., Baczy\u0144ska, D., Janczak, D., and Sk\u00f3ra, J.P. (2022). Two-Stage Gene Therapy (VEGF, HGF and ANG1 Plasmids) as Adjunctive Therapy in the Treatment of Critical Lower Limb Ischemia in Diabetic Foot Syndrome. Int. J. Environ. Res. Public. Health, 19.","DOI":"10.3390\/ijerph191912818"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jvs.2010.07.044","article-title":"Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: Results of the HGF-0205 trial","volume":"52","author":"Powell","year":"2010","journal-title":"J. Vasc. Surg."},{"key":"ref_111","first-page":"655","article-title":"Application of VEGF165 plasmid in treatment of critical lower limb ischemia","volume":"20","author":"Pupka","year":"2006","journal-title":"Pol. Merkur. Lek. Organ. Pol. Tow. Lek."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/gt.2015.110","article-title":"Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia","volume":"23","author":"Kibbe","year":"2016","journal-title":"Gene Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/mt.2013.69","article-title":"Phase 1\/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy","volume":"21","author":"Christiansen","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_114","first-page":"669","article-title":"Stromal Cell-Derived Factor-1 Plasmid Treatment for Patients with Peripheral Artery Disease (STOP-PAD) Trial: Six-Month Results","volume":"27","author":"Hammad","year":"2020","journal-title":"J. Endovasc. Ther. Off. J. Int. Soc. Endovasc. Spec."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/mt.2008.33","article-title":"Therapeutic Angiogenesis with Intramuscular NV1FGF Improves Amputation-free Survival in Patients with Critical Limb Ischemia","volume":"16","author":"Nikol","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(11)60394-2","article-title":"Effect of fibroblast growth factor NV1FGF on amputation and death: A randomised placebo-controlled trial of gene therapy in critical limb ischaemia","volume":"377","author":"Belch","year":"2011","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"186215","DOI":"10.1155\/2013\/186215","article-title":"Gene therapy and cell-based therapies for therapeutic angiogenesis in peripheral artery disease","volume":"2013","author":"Shimamura","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1871522213999131231105139","article-title":"Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent","volume":"14","author":"Sanada","year":"2014","journal-title":"Immunol. Endocr. Metab. Agents Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1024\/0301-1526\/a000298","article-title":"Gene therapy for therapeutic angiogenesis in peripheral arterial disease\u2014A systematic review and meta-analysis of randomized, controlled trials","volume":"42","author":"Hammer","year":"2013","journal-title":"VASA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40256-016-0210-3","article-title":"Results of an International Postmarketing Surveillance Study of pl-VEGF165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease","volume":"17","author":"Deev","year":"2017","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1753944718786926","article-title":"Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication","volume":"12","author":"Deev","year":"2018","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1582-4934.2008.00454.x","article-title":"Liposome-based vascular endothelial growth factor-165 transfection with skeletal myoblast for treatment of ischaemic limb disease","volume":"14","author":"Ye","year":"2010","journal-title":"J. Cell Mol. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1067\/mva.2000.107566","article-title":"Induction of angiogenesis by cationic lipid-mediated VEGF165 gene transfer in the rabbit ischemic hindlimb model","volume":"32","author":"Gowdak","year":"2000","journal-title":"J. Vasc. Surg."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"122799","DOI":"10.1016\/j.biomaterials.2024.122799","article-title":"\u201cAll in one\u201d lipid-polymer nanodelivery system for gene therapy of ischemic diseases","volume":"313","author":"Chen","year":"2025","journal-title":"Biomaterials"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1073\/pnas.1117885109","article-title":"Syndecan-4 proteoliposomes enhance fibroblast growth factor-2 (FGF-2)-induced proliferation, migration, and neovascularization of ischemic muscle","volume":"109","author":"Jang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/v2020334","article-title":"Development of viral vectors for use in cardiovascular gene therapy","volume":"2","author":"Williams","year":"2010","journal-title":"Viruses"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: Overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/10430340460732445","article-title":"Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates","volume":"15","author":"Palmer","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","article-title":"Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication","volume":"108","author":"Rajagopalan","year":"2003","journal-title":"Circulation"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","article-title":"Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European union","volume":"20","year":"2012","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_133","first-page":"106","article-title":"Viral vectors for vascular gene therapy","volume":"7","author":"Fischer","year":"2002","journal-title":"Exp. Clin. Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0008-6363(01)00546-6","article-title":"AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model","volume":"53","author":"Shimpo","year":"2002","journal-title":"Cardiovasc. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2045-824X-5-13","article-title":"Arteriogenic therapy based on simultaneous delivery of VEGF-A and FGF4 genes improves the recovery from acute limb ischemia","volume":"5","author":"Jazwa","year":"2013","journal-title":"Vasc. Cell"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Patel, D.H., Talele, D., and Talele, C. (2025). Gene delivery using viral vectors. Challenges in Delivery of Therapeutic Genomics and Proteomics, Elsevier.","DOI":"10.1016\/B978-0-443-27416-9.00010-1"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Wirth, G., Juusola, G., Laakso, H., Laham-Karam, N., Yl\u00e4-Herttuala, S., and Korpisalo, P. (2025). Sustained capillary enlargement induced by angiogenic gene therapy does not support post-ischemic muscle recovery of hyperlipidemic mice. Front. Bioeng. Biotechnol., 13.","DOI":"10.3389\/fbioe.2025.1512962"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/jgm.287","article-title":"Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ","volume":"4","author":"Vajanto","year":"2002","journal-title":"J. Gene Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"18769","DOI":"10.1073\/pnas.0910561106","article-title":"Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice","volume":"106","author":"Sarkar","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s12668-019-00688-y","article-title":"Adenoviral Vector Delivery of vegf, Angiogenin, and gdnf Genes Promotes Angiogenesis in Ischemic Skeletal Muscle","volume":"10","author":"Samatoshenkov","year":"2020","journal-title":"BioNanoScience"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.omtm.2023.08.007","article-title":"Toward lentiviral vectors for antiangiogenic ocular gene therapy","volume":"30","author":"Askou","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s11626-017-0151-4","article-title":"ETV-2 activated proliferation of endothelial cells and attenuated acute hindlimb ischemia in mice","volume":"53","author":"Vu","year":"2017","journal-title":"Vitr. Cell Dev. Biol. Anim."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"189","DOI":"10.15419\/psc.v4i01.193","article-title":"Co-injection of ETV-2 and HGF viral vectors significantly improve angiogenesis in mice with hindlimb ischemia","volume":"4","author":"Pham","year":"2017","journal-title":"Prog. Stem Cell"},{"key":"ref_144","first-page":"1539","article-title":"Intramuscular injection of lentivirus-mediated EPAS1 gene improves hind limb ischemia and its mechanism in a rat model of peripheral artery vascular disease","volume":"33","author":"Wang","year":"2017","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi Chin. J. Cell Mol. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/CIRCULATIONAHA.110.009407","article-title":"Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication","volume":"124","author":"Creager","year":"2011","journal-title":"Circulation"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.vph.2018.10.005","article-title":"Beyond endothelial cells: Vascular endothelial growth factors in heart, vascular anomalies and placenta","volume":"112","author":"Laakkonen","year":"2019","journal-title":"Vasc. Pharmacol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ncb1486","article-title":"VEGF Controls Endothelial-Cell Permeability by Promoting the Beta-Arrestin-Dependent Endocytosis of VE-Cadherin","volume":"8","author":"Gavard","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/joim.12821","article-title":"Blockade of vascular endothelial growth factor receptor 2 inhibits intraplaque haemorrhage by normalization of plaque neovessels","volume":"285","author":"Parma","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_149","first-page":"1667","article-title":"Mouse model of angiogenesis","volume":"152","author":"Couffinhal","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/nprot.2009.185","article-title":"Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia","volume":"4","author":"Limbourg","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1161\/01.CIR.99.1.111","article-title":"Age-dependent impairment of angiogenesis","volume":"99","author":"Rivard","year":"1999","journal-title":"Circulation"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Okonkwo, U.A., and DiPietro, L.A. (2017). Diabetes and Wound Angiogenesis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071419"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1172\/JCI18420","article-title":"Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis","volume":"113","author":"Ozawa","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"H629","DOI":"10.1152\/ajpheart.00126.2012","article-title":"Nonviral gene therapy targeting cardiovascular system","volume":"303","author":"Su","year":"2012","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1161\/CIRCRESAHA.115.303565","article-title":"Modulating the vascular response to limb ischemia: Angiogenic and cell therapies","volume":"116","author":"Cooke","year":"2015","journal-title":"Circ. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13287-019-1276-z","article-title":"Therapeutic angiogenesis using stem cell-derived extracellular vesicles: An emerging approach for treatment of ischemic diseases","volume":"10","author":"Bian","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/gt.2010.51","article-title":"Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia","volume":"17","author":"Shigematsu","year":"2010","journal-title":"Gene Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/1074248415574336","article-title":"pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients with Chronic Lower Limb Ischemia","volume":"20","author":"Deev","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.ymthe.2019.10.017","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia","volume":"27","author":"Gu","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10456-025-09979-3","article-title":"SDF-1\u03b1 mRNA therapy in peripheral artery disease","volume":"28","author":"Zhang","year":"2025","journal-title":"Angiogenesis"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"102592","DOI":"10.1016\/j.omtn.2025.102592","article-title":"mRNA-based in vivo induction of ETV2 to restore blood flow in a preclinical mouse hindlimb ischemia model","volume":"36","author":"Toyonaga","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2019.08.014","article-title":"Cell-mediated delivery of VEGF modified mRNA enhances blood vessel regeneration and ameliorates murine critical limb ischemia","volume":"310","author":"Yu","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"eaav8521","DOI":"10.1126\/scitranslmed.aav8521","article-title":"Advances in therapeutic applications of extracellular vesicles","volume":"11","author":"Wiklander","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.cell.2017.10.025","article-title":"In Vivo Target Gene Activation via CRISPR\/Cas9-Mediated Trans-epigenetic Modulation","volume":"171","author":"Liao","year":"2017","journal-title":"Cell"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"100073","DOI":"10.1016\/j.celbio.2025.100073","article-title":"Biomaterial scaffold-based gene delivery for the repair of complex wounds: Challenges, progress, and future perspectives","volume":"1","author":"McGrath","year":"2025","journal-title":"Cell Biomater."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/12\/1104\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:24:27Z","timestamp":1781774667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/12\/1104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":168,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cells15121104"],"URL":"https:\/\/doi.org\/10.3390\/cells15121104","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}